|Day Low/High||29.93 / 31.10|
|52 Wk Low/High||12.04 / 31.98|
Momenta may be a good option for value-oriented investors, while Coherus may be better for those who prefer a company that is likely to gain momentum.
No Payment Due upon Return, no Obligations for Future Payments or Royalties
Year to date, shares of AbbVie are up 7%. With a gigantic patent battle looming, can the stock go higher?
Continued execution on multiple fronts positions the company strongly for the second-half of 2016 and beyond
BLA submission anticipated in the third quarter 2016
Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.
Patent Trial and Appeal Board Institutes Two Additional IPRs Against AbbVie's Patents
Biosimilar to etanercept meets primary endpoint
USPTO Issued Coherus U.S. Patents 9,340,611; 9,340,612 and 9,346,880
AbbVie and Gilead Sciences are worth accumulating in a long and deep bear market for biotech.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Trade-Ideas LLC identified Coherus BioSciences (CHRS) as a weak on high relative volume candidate
Investors eyeing a purchase of Coherus BioSciences Inc stock, but tentative about paying the going market price of $18.75/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $17.50 strike, which has a bid at the time of this writing of $1.80.